Aquestive Therapeutics Inc (AQST) News

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

WARREN, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or...

Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

WARREN, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or...

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world...

Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

WARREN, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 8-K - Current report

Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

On track to submit Anaphylm™ (epinephrine) Sublingual Film NDA in Q1 2025Actively recruiting subjects in the...

Form 8-K - Current report

Aquestive Therapeutics Receives U.S. FDA Orphan Drug Exclusivity for Libervant® (diazepam) Buccal Film in Pediatric Patients with Seizure Clusters Ages Two to Five

WARREN, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or...

Form 8-K - Current report

Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film

Reaffirms New Drug Application (NDA) first quarter 2025 submission guidanceConfirms no additional adult...

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]